What is the 13F Pro Quality Score for ALC?

13F Pro ranks ALCON INC (ALC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ALC's current score at https://13fpro.ai/company/ALC (free sign-up required for the full ranking).

Which hedge funds own the most ALC stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ALC include VANGUARD CAPITAL MANAGEMENT, Bank of New York Mellon, NORGES BANK. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ALC as soon as new 13F filings post.

Where does 13F Pro source ALC data?

All ALCON INC fundamentals and ownership data come directly from SEC EDGAR. ALCON INC files with the SEC under CIK 1167379. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ALC in?

ALCON INC (ALC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ALC research updated on 13F Pro?

ALC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ALCON INC(ALC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1167379 ALC stock profile & AI dashboard →

13F Pro Quality Score

54.9/100

Rank #1,288 of 2,961 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

53.8/100

Profitability

56.1/100

Balance Sheet

55.0/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

86.9/100

Revenue Scale

86.2/100

Dilution Risk

94.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ALC Scores 55/100

exact factor attribution · 2026-09-11

ALC's composite is driven by scale and shareholder dilution, held back by free cash flow and earnings quality. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+5.4 pts

86th pct

Shareholder dilution

+2.2 pts

95th pct

Institutional flow

+1.9 pts

87th pct

Profitability

+0.9 pts

56th pct

Revenue growth

+0.8 pts

54th pct

Capital efficiency

+0.5 pts

55th pct

Earnings growth

-1.8 pts

15th pct

Earnings quality

-2.0 pts

30th pct

Free cash flow

-3.0 pts

30th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ALC Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for ALCON INC (ALC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALC at 54.9/100 on a 32-signal composite quality model, placing it at rank #1,288 of 2,961 stocks — the top half of the AI-ranked universe. ALC scores in the top quartile across institutional flow (86.9), revenue scale (86.2). Areas of concern include free cash flow (30.0) and earnings quality (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (FY 2025), ALCON INC reports quarterly revenue of $10.4B, net income of $980.0M. Top institutional holders of ALC by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Bank of New York Mellon, NORGES BANK, based on the most recent SEC filings. ALC trades on the NYSE exchange and files with the SEC under CIK 1167379. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ALCON INC directly from SEC EDGAR.

✦

Fun facts about ALCON INC

Quirks, history, and lore behind ALC — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · large-cap · listed on the NYSE · headquartered in Texas.
2
The Numbers
Annual revenue around $9–10 billion, with operations in over 60 countries and tens of thousands of employees worldwide.
3
The History
Originally founded as part of Nestlé's healthcare portfolio, it was later spun off by Novartis as a standalone publicly traded company around 2019.
4
The Secret
It is one of the world's largest dedicated eye-care companies, focused entirely on surgical and vision care products — not a single pill in the portfolio.
5
The Lore
Its products help treat cataracts, glaucoma, and dry eye — and it makes some of the most widely implanted intraocular lenses on the planet.
6
The Giveaway
If you've ever had cataract surgery or worn TOTAL30 contact lenses, there's a good chance this Fort Worth eye-care giant had a hand in it.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

FY 2025

$10.4B

Net Income

FY 2025

$980.0M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+4.9% YoY

$10.40BFY 2025

FY22 $8.72BFY23 $9.46BFY24 $9.91BFY25 $10.40B

Total Assets

+4.0% YoY

$31.55BFY 2025

FY22 $29.16BFY23 $29.61BFY24 $30.35BFY25 $31.55B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$10.40B +4.9%	$9.91B +4.8%	$9.46B +8.5%	$8.72B +5.1%	$8.29B +21.3%	$6.83B
Total Assets	$31.55B +4.0%	$30.35B +2.5%	$29.61B +1.5%	$29.16B +4.2%	$28.00B +1.4%	$27.60B

Get alerted when ALC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ALCON INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ALC

VANGUARD CAPITAL MANAGEMENT LLC
$994.6M14,749,582 sh
Bank of New York Mellon Corp
$876.2M13,057,962 sh
NORGES BANK
$741.4M10,976,697 sh
Invesco Ltd.
$696.5M10,380,332 sh
AKO CAPITAL LLP
$651.9M9,683,004 sh
Aristotle Capital Management, LLC
$614.3M9,154,828 sh
Zurcher Kantonalbank (Zurich Cantonalbank)
$535.8M7,915,741 sh
FMR LLC
$514.2M7,662,988 sh
UBS Group AG
$480.2M7,156,307 sh
Amundi
$445.4M6,637,563 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$994.6M	14,749,582
Bank of New York Mellon Corp	$876.2M	13,057,962
NORGES BANK	$741.4M	10,976,697
Invesco Ltd.	$696.5M	10,380,332
AKO CAPITAL LLP	$651.9M	9,683,004
Aristotle Capital Management, LLC	$614.3M	9,154,828
Zurcher Kantonalbank (Zurich Cantonalbank)	$535.8M	7,915,741
FMR LLC	$514.2M	7,662,988
UBS Group AG	$480.2M	7,156,307
Amundi	$445.4M	6,637,563

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ALC on your watchlist

Track score changes the day ALCON INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ALC a good stock to buy?

13F Pro's AI-powered analysis of ALCON INC (ALC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALC are available on the ALC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ALC is classified as a large company.

Which hedge funds own ALC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ALCON INC's investment landscape.